Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 6/20 | 0.54 |
| ▸ | NPC1 | O15118 | 5/20 | 0.54 |
| ▸ | NQO2 | P16083 | 1/20 | 0.54 |
| ▸ | CASP3 | P42574 | 1/20 | 0.54 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | TP53 | P04637 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 4/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.52 |
| ▸ | POLB | P06746 | 3/20 | 0.52 |
| ▸ | PKM | P14618 | 3/20 | 0.51 |
| ▸ | MAPT | P10636 | 5/20 | 0.51 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2815613 | 0.91 | NPC1 (0.57) | RAB9ANPC1NQO2CASP3SENP7 | |
| SCHEMBL2817574 | 0.89 | NPC1 (0.54) | RAB9ANPC1NQO2CASP3SENP7 | |
| SCHEMBL2814430 | 0.88 | NPC1 (0.53) | RAB9ANPC1NQO2CASP3SENP7 | |
| SCHEMBL2817852 | 0.88 | NPC1 (0.53) | RAB9ANPC1NQO2CASP3SENP7 | |
| SCHEMBL2816719 | 0.88 | NPC1 (0.53) | RAB9ANPC1NQO2CASP3SENP7 | |
| SCHEMBL2819873 | 0.88 | NPC1 (0.53) | RAB9ANPC1NQO2CASP3SENP7 | |
| SCHEMBL4448335 | 0.87 | RAB9A (0.44) | RAB9ANPC1NQO2CASP3SENP7 | |
| SCHEMBL2817108 | 0.87 | MAPT (0.59) | RAB9ANPC1NQO2CASP3SENP7 | |
| SCHEMBL2814757 | 0.87 | NPC1 (0.52) | RAB9ANPC1NQO2CASP3SENP7 | |
| SCHEMBL4448336 | 0.86 | RAB9A (0.43) | RAB9ANPC1NQO2CASP3SENP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100249123-A1 | NOVEL BENZAMIDE DERIVATIVES AS MODULATORS OF THE FOLLICLE STIMULATING HORMONE | ADDEX PHARMA SA (CH) | 2010-09-30 | — | — | US | claimed |
| EP-2134676-A2 | NOVEL BENZAMIDE DERIVATIVES AS MODULATORS OF THE FOLLICLE STIMULATING HORMONE | Addex Pharma SA (CH) | 2009-12-23 | — | — | EP | claimed |
| WO-2008117175-A2 | NOVEL BENZAMIDE DERIVATIVES AS MODULATORS OF THE FOLLICLE STIMULATING HORMONE | ADDEX PHARMA SA (CH) | 2008-10-02 | — | — | WO | claimed |
| US-20100249123-A1 | NOVEL BENZAMIDE DERIVATIVES AS MODULATORS OF THE FOLLICLE STIMULATING HORMONE | ADDEX PHARMA SA (CH) | 2010-09-30 | — | — | US | disclosed |
| EP-2134676-A2 | NOVEL BENZAMIDE DERIVATIVES AS MODULATORS OF THE FOLLICLE STIMULATING HORMONE | Addex Pharma SA (CH) | 2009-12-23 | — | — | EP | disclosed |
| WO-2008117175-A2 | NOVEL BENZAMIDE DERIVATIVES AS MODULATORS OF THE FOLLICLE STIMULATING HORMONE | ADDEX PHARMA SA (CH) | 2008-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249123-A1 | NOVEL BENZAMIDE DERIVATIVES AS MODULATORS OF THE FOLLICLE STIMULATING HORMONE | FSHR, GNRHR, SHBG | RAB9A 1404/4885NPC1 3400/4885NQO2 856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.